Roche (SIX: RO, ROG; OTCQX: RHHBY) and Biogen Idec (NASDAQ: BIIB) today announced their decision to discontinue the ocrelizumab clinical development programme in patients with rheumatoid arthritis (RA). Following a detailed analysis of the efficacy and safety results from the RA programme, the companies concluded that the overall benefit to risk profile of ocrelizumab was not favourable in RA taking into account the currently available treatment options. The ocrelizumab RA program included four Phase III studies (SCRIPT, FILM, FEATURE, and STAGE)…

See the original post here:
Roche And Biogen Idec Announce Their Decision To Discontinue The Ocrelizumab Clinical Development Programme In Patients With Rheumatoid Arthritis

You may also like:

• ZOLL Defibrillators Are Ranked Number One In User Satisfaction
• Women With Hypoactive Sexual Desire Disorder (HSDD) Report That Flibanserin Increased Their Sexual Desire And Reduced Associated Distress
• Conceptus(R) Receives FDA Approval On Essure’s Bilateral Placement Rate To 96.9%
• Preliminary U.S. Registration Strategy For Investigational Drug, Hematide™ / Peginesatide, To Treat Anemia In Chronic Renal Failure
• Biogen Idec And Swedish Orphan Biovitrum Present Data On Long-Lasting Hemophilia B Therapy At The World Federation Of Hemophilia Congress
• Clinuvel Unveils SCENESSE(R) Following European Brand Approval
• Lancet Article Highlights Hope In The Tuberculosis Drug Development Pipeline
• Restored Hearing Making Sound Success
• Enzon Opens A Phase 2 Study Of PEG-SN38 For Metastatic Breast Cancer
• Genentech Submits Supplemental Applications To FDA For Avastin Combined With Commonly Used Chemotherapies For Women With Advanced Breast Cancer